Table 1.
Clinical characteristics of patients evaluable for analysis at TP5 and TP6
| Healthy controls | Solid cancers | Hematologic malignancies | ||||
|---|---|---|---|---|---|---|
| TP5 | TP6 | TP5 | TP6 | TP5 | TP6 | |
| Total numbers | 22 | 26 | 50 | 48 | 35 | 38 |
| Age | ||||||
| Median (Q1–Q3) years | 41 (34.25–49.75) | 41 (33.25–49.75) | 70 (55–74) | 71 (52–74) | 66 (57–70) | 66 (59–70) |
| Sex | ||||||
| Male | 11/22 (50%) | 13/26 (50%) | 18/50 (36%) | 17/48 (35%) | 19/35 (54%) | 27/38 (71%) |
| Female | 11/22 (50%) | 13/26 (50%) | 32/50 (64%) | 31/48 (65%) | 16/35 (46%) | 11/38 (29%) |
| Race | ||||||
| Caucasian | 13/22 (59%) | 16/26 (62%) | 33/50 (66%) | 34/48 (71%) | 17/35 (49%) | 22/38 (58%) |
| BAME | 9/22 (41%) | 10/26 (38%) | 13/50 (26%) | 9/48 (19%) | 5/35 (14%) | 7/38 (18%) |
| Unspecified | 4/50 (8%) | 5/48 (10%) | 13/36 (37%) | 9/38 (24%) | ||
| Tumor types | ||||||
| Women's cancers (gynecological, breast) | 20/50 (40%) | 17/48 (35%) | ||||
| Urological cancers (renal, prostate, bladder) | 5/50 (10%) | 5/48 (10%) | ||||
| Skin cancers (melanoma, Merkel cell) | 5/50 (10%) | 5/48 (10%) | ||||
| Thoracic malignancies (lung, mesothelioma) | 7/50 (14%) | 4/48 (8%) | ||||
| GI cancers | 11/50 (22%) | 13/48 (27%) | ||||
| Head and neck cancers | 2/50 (4%) | 2/48 (4%) | ||||
| Brain cancers | — | 2/48 (4%) | ||||
| Mature B-cell neoplasms | 17/35 (49%) | 20/38 (53%) | ||||
| Chronic lymphocytic leukemia | 2 | 3 | ||||
| Plasma cell Myeloma | 8 | 10 | ||||
| Diffuse large B-cell lymphoma | 0 | 1 | ||||
| Follicular lymphoma | 2 | 2 | ||||
| Mantle cell lymphoma | 1 | 1 | ||||
| MALT lymphoma | 2 | 1 | ||||
| Hodgkin lymphoma | 1 | 1 | ||||
| Post-transplant lymphoproliferative disorder | 1 | 1 | ||||
| Mature T-cell neoplasms | 2/35 (6%) | 2/38 (5%) | ||||
| Anaplastic large cell lymphoma | 2 | 1 | ||||
| Angioimmunoblastic T-cell lymphoma | 0 | 1 | ||||
| Myeloid and acute leukemia neoplasm | 15/35 (43%) | 15/38 (39%) | ||||
| Myelodysplastic syndrome (MDS) | 14 a | 13 b | ||||
| Acute myeloid leukemia | ||||||
| Chronic myelomonocytic leukemia | 0 | 1 | ||||
| T-cell acute lymphoblastic leukemia | ||||||
| Myelofibrosis | 1 | 1 | ||||
| Others | 1/35 (3%) | 1/38 (3%) | ||||
| Amyloid light-chain (AL) amyloidosis | 1 | 1 | ||||
| TNM staginga (solids only) | ||||||
| 1 | 5/50 (10%) | 4/48 (8%) | ||||
| 11 | 6/50 (12%) | 7/48 (15%) | ||||
| 111 | 11/50 (22%) | 11/48 (23%) | ||||
| 1V | 27/50 (54%) | 23/48 (48%) | ||||
| Missing data | 1/50 (2%) | 3/48 (6%) | ||||
| Time from cancer diagnosis to study recruitment | ||||||
| <3 months | 9/50 (18%) | 7/48 (15%) | 4/35 (11%) | 3/38 (8%) | ||
| 3–12 months | 9/50 (18%) | 12/48 (25%) | 5/35 (14%) | 7/38 (18%) | ||
| 12–24 months | 16/50 (32%) | 13/48 (27%) | 2/35 (6%) | 4/38 (11%) | ||
| >24 months | 14/50 (28%) | 14/48 (29%) | 19/35 (54%) | 21/38 (55%) | ||
| Missing info | 2/50 (4%) | 2/48 (4%) | 5/35 (14%) | 3/38 (8%) | ||
| Median time from dose 2 to blood sampling at TP5 | ||||||
| Median (Q1–Q3) days | 215.5 (200–259) | 187 (180–213) | 188 (180.5–196) | |||
| Median time from dose 3 to blood sampling at TP6 | ||||||
| Median (Q1–Q3) days | 21 (21–23.75) | 21 (21–24) | 21 (20–25) | |||
NOTE: TP5 = blood sampling prior to the third dose; TP6 = 3 weeks after the third vaccine dose of the BNT162b2 vaccine.
a12/14 patients with TP5 sample available had received ChAdOx1 nCov-19 as the first and/or second dose.
b9/13 patients with TP6 sample available had received ChAdOx1 nCov-19 as the first and/or second dose.